One reason for FDA deprioritizationOn doing a Google seach for "FDA Deprioritization", I came across an article " FDA Winners and Losers in COVID19 Therapies" dated 3rd July. Paragraph 6, explains why some plausible COVID therpies are deprioritized - time required for manufacturing and scaling up. A FDA director is quoted as saying “We’re seeing so much delay in bringing products to market because folks just are not paying attention to the manufacturing issues.”
This "criteria" for deprioritization was public knowledge in early July, long before Sona submitted their FDA EUA application. We cannot just blame it on recent changes to FDA templates or politics.
https://www.pharmaceutical-technology.com/comment/fda-winners-losers-covid-19-therapies/